Welcome to our dedicated page for Anebulo Pharmaceuticals news (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals stock.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is a clinical-stage pharmaceutical company developing selonabant (ANEB-001), a CB1 receptor antagonist drug candidate for acute cannabis-induced toxicity and related cannabinoid-induced toxic effects. The ANEB news feed on Stock Titan aggregates the company’s press releases and market-moving updates so readers can follow how its development and corporate plans evolve over time.
News about Anebulo frequently centers on its clinical program for selonabant. The company has reported results from a Phase 2 proof-of-concept trial of oral selonabant in adults challenged with oral THC, as well as the initiation of a Phase 1 single ascending dose study of an intravenous formulation in healthy young adults. Updates often describe study design, safety and tolerability observations, and the role of selonabant as a potential antidote for acute cannabis-induced toxicity, particularly in pediatric patients.
Investors and observers can also find regulatory and funding developments in Anebulo’s news. The company has announced interactions with the U.S. Food and Drug Administration regarding the development path for IV selonabant, grant awards from the National Institute on Drug Abuse (NIDA) to support its clinical work, and private placement financings and loan arrangements that provide capital for ongoing research and development.
Another recurring theme in ANEB news is the company’s strategic and corporate actions, including a proposed going private transaction, a previously announced reverse stock split structure, and a later decision to pursue a voluntary self-tender offer to repurchase shares as part of its plan to reduce the number of stockholders. By reviewing the ANEB news page, readers can track clinical milestones, regulatory interactions, grant funding, financing events, and corporate governance decisions that Anebulo discloses through its press releases.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced on December 22, 2025 that its Board will commence a voluntary self tender offer to purchase up to 300,000 shares at $3.50 per share in lieu of a previously proposed reverse stock split (proposed ratios: 1-for-2,500 to 1-for-7,500).
The Board said costs tied to fractional-share payments after the split—driven by holders opening multiple small accounts—now outweigh benefits, so the reverse split is abandoned and a tender offer will be filed on Schedule TO with the SEC. Tender documents will be distributed to stockholders and made available at www.sec.gov.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported Q1 FY2026 results and program updates on November 13, 2025. Key updates include first subjects dosed in a FDA-cleared Phase 1 single ascending dose (SAD) IV study of selonabant for acute cannabis-induced toxicity and a $994,300 second-year NIDA grant tranche to support the SAD study. The company cited a prior successful Phase 2 oral selonabant trial in adults and ongoing FDA collaboration for pediatric development. Corporate actions include a Board-approved proposed reverse stock split tied to a possible going-private transaction, with shareholder approval pending and a special meeting delayed by SEC comment resolution affected by a government shutdown. Q1 operating expenses were $2.3M, net loss $2.2M (loss per share $(0.05)), and cash of $10.4M with an additional $3.0M loan available.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported its Q4 and FY2025 financial results while announcing significant progress in its clinical programs. The company has initiated dosing in a Phase 1 single ascending dose (SAD) study of an intravenous formulation of selonabant, their lead drug candidate for treating acute cannabis-induced toxicity in children.
Key financial metrics include Q4 operating expenses of $2.3M (up from $1.3M in Q4 2024), a Q4 net loss of $2.1M, and cash position of $11.6M as of June 30, 2025. The company secured a $994,300 grant from NIDA to support their ongoing SAD study.
Additionally, Anebulo announced plans for a reverse stock split as part of a proposed going private transaction, aimed at maintaining fewer than 300 record holders to avoid SEC reporting requirements.
Anebulo Pharmaceuticals (Nasdaq: ANEB) has initiated dosing in its Phase 1 single ascending dose (SAD) study of intravenous selonabant for acute cannabis-induced toxicity. The study, supported by a $994,300 NIDA collaborative grant, aims to develop the first emergency antidote for cannabis toxicity.
The company is prioritizing the IV formulation specifically for pediatric patients, following successful Phase 2 trials of oral selonabant in adults. This strategic focus stems from children's heightened sensitivity to cannabis toxicity, which can lead to severe complications including CNS depression, respiratory depression, coma, and potentially death.
The FDA has indicated strong interest in collaborating with Anebulo to address this growing unmet medical need in pediatric cannabis toxicity treatment.
Anebulo Pharmaceuticals (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on cannabinoid-induced toxicities treatments, has provided an update on its previously announced going private transaction from July 23, 2025. The company has received interest from potential financial and strategic partners, prompting the Board to review all strategic alternatives.
The strategic options under consideration include the proposed going private transaction and reverse stock split, a potential sale of company assets, and possible merger transactions. While this review is ongoing, Anebulo plans to proceed with a special stockholder meeting to vote on the proposed reverse stock split, though the Board maintains discretion to abandon the split even if approved.
Anebulo Pharmaceuticals (Nasdaq: ANEB) has announced plans to go private through a significant reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500. The company will pay $3.50 per pre-split share in cash for fractional shares, representing a 91% premium over the July 22, 2025 closing price.
Stockholders holding fewer than the minimum number of shares (between 2,500 and 7,500) will be cashed out, while larger holders will receive one post-split share for every minimum number of pre-split shares. The company cites burdensome costs of being a public reporting company as the primary reason for this decision, aiming to focus on product development and cost reduction.
Anebulo Pharmaceuticals (NASDAQ: ANEB) reported its Q3 FY2025 financial results and provided updates on its clinical development program. The company is advancing intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced Central Nervous System (CNS) depression. Anebulo plans to initiate a Phase 1 single ascending dose (SAD) study in healthy adult volunteers aged 18-25 years in Q3 2025.
Financial highlights include operating expenses of $1.9 million (vs $1.7M in Q3 FY2024), a net loss of $1.7 million or $(0.04) per share, and cash and cash equivalents of $13.3 million as of March 31, 2025. The company has access to an additional $3 million through a Loan Agreement.
Anebulo Pharmaceuticals (ANEB) reported Q2 FY2025 financial results and updates on their lead product candidate, selonabant, designed to treat acute cannabis-induced toxic effects. The company secured $15 million through a private placement of 15.2 million shares and amended its Loan Security Agreement to $3 million.
Key developments include FDA discussions regarding intravenous selonabant development, with the agency acknowledging the unmet need for treating cannabis toxicity in children. The company plans to begin Phase 1 single ascending dose study in 1H25.
Financial results show operating expenses of $2.6 million in Q2 FY2025, down from $2.8 million year-over-year. Net loss was $2.5 million ($0.09 per share) compared to $2.7 million ($0.11 per share) in Q2 FY2024. Cash position stands at $15.0 million as of December 31, 2024.
Anebulo Pharmaceuticals (ANEB) announced positive regulatory progress for selonabant in treating acute cannabis-induced toxicity in children and secured a $15 million capital raise. The company's Phase 2 proof-of-concept study with 134 adult subjects demonstrated that oral selonabant effectively blocked or reversed key CNS effects of THC. The FDA acknowledged the unmet need for treating children exposed to cannabis toxicity and proposed ongoing collaboration.
The company secured a private placement of 15.2 million shares at $0.99 per share, priced at-the-market under Nasdaq rules. Additionally, Anebulo will modify its Loan and Security Agreement, reducing the maximum loan size to approximately $3 million. The company plans to initiate a Phase I SAD study of IV selonabant in healthy adults in first half of 2025.
Anebulo Pharmaceuticals (ANEB) has reported its Q1 FY2025 financial results and updates. The company received the first tranche of a $1.9 million NIDA grant to advance its intravenous selonabant formulation for treating acute cannabis-induced toxicities. The company plans to complete IND-enabling activities by end of 2024 and enroll first volunteers in H1 2025. Financial results show operating expenses of $2.4 million, with a net loss of $2.2 million ($0.08 per share). Cash position stands at $1.4 million, with access to an additional $10 million through a recent Loan Agreement.
FAQ
What is the current stock price of Anebulo Pharmaceuticals (ANEB)?
What is the market cap of Anebulo Pharmaceuticals (ANEB)?
